MetaVia reports FY2024 net loss $27.6M; cash $16.0M funds into Q3 2025; DA-1726 data expected April

MetaVia Inc.

Net loss $27.6M ($3.56/share) vs $12.5M ($2.46/share) in 2023; R&D expenses rose to $21.6M from $9.2M.
Cash $16.0M as of Dec 31, 2024 (down from $22.4M); expected to fund operations into Q3 2025.
DA-1726: Top-line data from additional MAD Part 2 cohorts expected April 2025; proof-of-concept study planned Q4 2025.
DA-1241: Phase 2a in MASH met primary endpoint (ALT reduction); full data at medical meeting 2025; FDA end-of-Phase 2 meeting H1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.